ArticleJCO precision oncology2022

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.

Timothy A Yap et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.